Get the Stockscreener App
23.31
0.77%
-0.18
After Hours:
23.29
-0.02
-0.09%
Denali Therapeutics Inc stock is traded at $23.31, with a volume of 2.52M.
It is down -0.77% in the last 24 hours and up +26.68% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
See More
Previous Close:
$23.49
Open:
$24.165
24h Volume:
2.52M
Relative Volume:
1.38
Market Cap:
$3.70B
Revenue:
$1.27M
Net Income/Loss:
$-508.02M
P/E Ratio:
-8.0918
EPS:
-2.8807
Net Cash Flow:
$-419.23M
1W Performance:
+10.89%
1M Performance:
+26.68%
6M Performance:
+39.00%
1Y Performance:
+65.44%
1-Day Range:
$23.21
$24.65
1-Week Range:
$20.92
$24.65
52-Week Range:
$12.58
$24.65
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
23.31 | 3.70B | 1.27M | -508.02M | -419.23M | -2.8807 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Denali Therapeutics StockAnalyst focus and sector check after a quiet news week - AD HOC NEWS
Denali to Sell Priority Review Voucher for $195M Cash Boost - TradingView
Denali Monetizes Rare Pediatric Disease Voucher In $195m Deal After Avlayah FDA Nod - Citeline News & Insights
Sector Update: Healthcare Stocks Advance Premarket Thursday - Moomoo
Denali Therapeutics Files 8-K Report Detailing Company Information and Latest Press Release – June 2026 - Minichart
Denali Therapeutics to sell priority review voucher for $195m - Investing.com
Denali Therapeutics Inc (DNLI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Denali Therapeutics Inc (DNLI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Denali to sell priority review voucher for $195M (DNLI:NASDAQ) - Seeking Alpha
Denali sells Rare Pediatric Disease Priority Review Voucher for $195M to fund neurodegenerative drug development. - Pluang
Denali Monetizes FDA Voucher to Advance CNS Pipeline - TipRanks
Denali Therapeutics Inc (DNLI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million - The Manila Times
Denali Therapeutics to Sell FDA Priority Review Voucher for $195 Million - TradingView
Denali Therapeutics (Nasdaq: DNLI) to sell pediatric priority review voucher for $195M - Stock Titan
Denali’s rare disease voucher sale brings in $195 million - Stock Titan
Denali Therapeutics stock hits 52-week high at 23.78 USD By Investing.com - Investing.com Nigeria
Denali Therapeutics Inc (DNLI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Denali Therapeutics Inc (DNLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Denali Therapeutics Inc (DNLI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Denali Therapeutics Inc (DNLI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Denali Therapeutics Inc (DNLI) Institutional Confidence - TradingKey
Transcript : Denali Therapeutics Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01 - marketscreener.com
UBS reiterates Denali Therapeutics stock rating citing Avlayah launch By Investing.com - Investing.com Nigeria
UBS reiterates Denali Therapeutics stock rating citing Avlayah launch - Investing.com
Denali Therapeutics Inc (DNLI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
(DNLI) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Denali Therapeutics Halts Parkinson Drug Collaboration With Biogen - HarianBasis.co
Denali Therapeutics (DNLI) Rallies Over 3% as Stock Tests Key Resistance LevelsStock Analysis - newsline.com
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names - Insider Monkey
10 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
LRRK2 inhibitor failure pushes Parkinson’s field toward genetic enrichment - biocentury.com
Denali Therapeutics stock (US24823R1077): Alzheimer’s data and Roche deal keep Wall Street watchin - AD HOC NEWS
Denali stock dips as Biogen-partnered Parkinson's disease study fails - MSN
Denali Therapeutics (DNLI) grants RSUs and stock options to director - Stock Titan
Denali Therapeutics (DNLI) director granted RSUs and options in new award - Stock Titan
Denali Therapeutics (DNLI) director receives RSU and stock option awards - Stock Titan
Director at Denali Therapeutics (NASDAQ: DNLI) receives RSUs and options - Stock Titan
Denali Therapeutics (DNLI) director receives new RSU and stock option grants - Stock Titan
Denali Therapeutics (DNLI) director granted RSUs and stock options in new equity awards - Stock Titan
Denali Therapeutics (NASDAQ: DNLI) details Baker RSU and stock option grants - Stock Titan
Denali Therapeutics (DNLI) 2026 meeting backs board slate, auditor and executive pay - Stock Titan
Responsive Playbooks and the DNLI Inflection - Stock Traders Daily
DNLI PE Ratio & Valuation, Is DNLI Overvalued - Intellectia AI
DNLI.O Technical Analysis & Stock Price Forecast - Intellectia AI
Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos - Insider Monkey
Does Denali Therapeutics (DNLI) Parkinson’s Setback Reveal a Deeper Shift in Its Neuroscience Strategy? - simplywall.st
DNLI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
DNLI Q1 loss narrower than expected, Avlayah approval boosts prospects - MSN
A Look At Denali Therapeutics (DNLI) Valuation After Phase 2b Trial Failure Refocuses Attention On Its Pipeline - Sahm
Biogen and Denali halt BIIB122 trial for idiopathic Parkinson’s - Parkinson's News Today
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):